Supernus Pharmaceuticals
Pharmaceuticals, 9715 Key West Ave, Rockville, Maryland, 20850, United States, 201-500 Employees
Phone Number: +30********
Who is SUPERNUS PHARMACEUTICALS
We are a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our extensive expertise in product developme...
Read More
-
Headquarters: 9715 Key West Ave, Rockville, Maryland, 20850, United States
-
Date Founded: 2005
-
Employees: 201-500
-
Revenue: $500 Million to $1 Billion
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from SUPERNUS PHARMACEUTICALS
Supernus Pharmaceuticals Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Supernus Pharmaceuticals
Answer: Supernus Pharmaceuticals's headquarters are located at 9715 Key West Ave, Rockville, Maryland, 20850, United States
Answer: Supernus Pharmaceuticals's phone number is +30********
Answer: Supernus Pharmaceuticals's official website is https://supernus.com
Answer: Supernus Pharmaceuticals's revenue is $500 Million to $1 Billion
Answer: Supernus Pharmaceuticals's SIC: 2834
Answer: Supernus Pharmaceuticals's NAICS: 325412
Answer: Supernus Pharmaceuticals has 201-500 employees
Answer: Supernus Pharmaceuticals is in Pharmaceuticals
Answer: Supernus Pharmaceuticals contact info: Phone number: +30******** Website: https://supernus.com
Answer: We are a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our extensive expertise in product development has been built over the past 30 years: initially as a standalone development organization, then as a U.S. subsidiary of Shire plc and, in late 2005, as Supernus Pharmaceuticals Inc. We market our products in the United States through our own specialty sales force and seek strategic collaborations with other pharmaceutical companies to license our products outside the United States. We market Qelbree (viloxazine extended-release) for the treatment of attention deficit/hyperactivity disorder (ADHD) in children ages 6 to 17. Trokendi XR (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, Oxtellar XR (extended-release oxcarbazepine) for the treatment of epilepsy, Apokyn (apomorphine hydrochloride injection) for the acute treatment of hypomobility in advanced Parkinsons disease (PD), Myobloc (rimabotulinumtoxinB) for the treatment of cervical dystonia and treatment of chronic sialorrhea in adults, and Xadago (safinamide) as an adjunctive treatment to levodopa/carbidopa in PD patients with hypomobility. We are also developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD in adults, apomorphine infusion pump for hypomobility in PD, SPN-820 (NV-5138) for treatment-resistant depression, and SPN-817 for the treatment of epilepsy.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month